Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05827536
Other study ID # GLK-IT-2023
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 30, 2023
Est. completion date July 31, 2024

Study information

Verified date October 2023
Source APR Applied Pharma Research s.a.
Contact Giorgio Reiner
Phone +41.91.6957020
Email giorgio.reiner@apr.ch
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, randomized, 2-way crossover, monocentric controlled study in patients (≥ 16 years old) with phenylketonuria (PKU). The comparison will be between the test product (PKU GOLIKE, a prolonged-release amino-acids (AAs) mixture) and standard of care.


Description:

The study will consist of a screening visit (V1), two treatment periods with two test days each and a final visit planned at the end of the second treatment period (V2). Test days will occur on two consecutive preferably non-working/school days (T1-T2 and T3-T4,) preferably over two consecutive weeks. Treatment days in the two periods will have to be the same days of the week. T1 should be within two weeks after V1. The study products will be self-administered at home. Following informed consent and verification of eligibility criteria, 20 patients with PKU will be randomized in a 1:1 ratio to one of the following two sequences: AB or BA where A=standard of care and B=PKU GOLIKE. In details: - AB: patients will receive 3 daily self-administrations of their usual standard of care for 2 consecutive days in the first period followed by 3 daily self-administrations of PKU GOLIKE for 2 consecutive days in thesecond period. - BA: patients will receive 3 daily self-administrations of PKU GOLIKE for 2 consecutive days in the first period followed by 3 daily self administrations of their usual standard of care for 2 consecutive days in the second period. No change in the randomization sequence will be allowed. Each patient will follow the same diet in terms of food, calories and nutrients ranges during the first days (T1 and T3) of each period and the same diet during the second days (T2 and T4) of each period, according to the age and body weight of the patient. The days before the test days each patient will follow her/his standard diet. PKU GOLIKE /standard of care will be the only protein substitute allowed on each test day, and no sports activities will be allowed on sampling days. Five blood spots will be collected on the second test day of each period. Timing of self-administrations, meals and blood spots will be standardized for each test day. On the test days, no food will be allowed outside of the defined time windows. The first self-administration of each test day will be performed after an overnight fasting (10 -12 h) and before any food intake. A patient's e-diary will be used to collect information on patient compliance, 24-hour blood spot collections, diet, daily activities, adverse events and event-related concomitant medications. Adverse events will be continuously monitored during the study, starting from informed consent. Adverse events will be collected by the patients (or by a parent/guardian) in the e-diary and during the telephone calls made by the Investigator to the patients. Moreover, patients (or parents/guardians) will be instructed to promptly report adverse events occurring during the study to the Investigator. The end of study (V2) will be performed (remotely, by phone) at the end ofthe second treatment period, within 2 weeks after the last test day. Patients prematurely discontinued from the study will be asked to attend (remotely, by phone) a discontinuation visit possibly taking place within 2 weeks from the last test day. At the final/discontinuation visit, the investigator will organize collection of blood spots test and residual PKU GOLIKE product from the patient's domicile through a dedicated courier service. The account of the e-diary will be inactivated.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date July 31, 2024
Est. primary completion date July 31, 2024
Accepts healthy volunteers No
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria: 1. Signed, informed consent obtained by the patient prior to beingenrolled into the study and prior to starting any data collection. For legally minor patients, signed written consent shall be obtained also by the parents/legal guardian 2. Male or female, aged =16 years. 3. Patients with a registered diagnosis of PKU 4. Ability and willingness to comply with all study procedures and availability for the duration of the study. 5. Patients with mean value of blood Phe >360 µM in the previous 12 months (calculated on at least 3 samples during the previous 12 months; the last sample should be preferably obtained in the 30 days preceding inclusion in the study). 6. Patient taking free-AA and/or GMP as usual amino-acidssupplementation. Exclusion Criteria: 1. Known or suspected hypersensitivity to any excipients/components of PKU GOLIKE. 2. Treatment with any drug therapy for PKU 3. Patient taking PKU GOLIKE as usual amino-acids supplementation 4. Patient taking LNAA as usual amino-acids supplementation 5. Any moderate to severe medical condition, which in the opinion of the Investigator would interfere with the study procedures or study outcome (reason to be provided) 6. Any current participation in another clinical trial involving investigational or marketed products in the 3 months prior to the inclusion in this study. 7. Pregnancy or lactation.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
PKU GOLIKE
PKU GOLIKE is a food for special medicinal purposes (FSMP) for the dietary management of PKU.
Standard of Care
Protein substitute

Locations

Country Name City State
Italy ASST Santi Paolo e Carlo, Presidio Ospedale San Paolo, Via Antonio di Rudinì 8 Milan

Sponsors (1)

Lead Sponsor Collaborator
APR Applied Pharma Research s.a.

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Phe blood concentration with dried blood spots (umol/L) on the second test day with Standard of Care right before product self-administration and before any food intake at 8:00 am(±15 min) on the second test day with SoC
Primary Phe blood concentration with dried blood spots (umol/L) on the second test day with GOLIKE PLUS right before product self-administration and before any food intake at 8:00 am(±15 min) on the second test day with Golike Plus
Primary Phe blood concentration with dried blood spots (umol/L) on the second test day with Standard of Care right before product self-administration and before food intake at 12:00 am (±15 min) on the second test day with SoC
Primary Phe blood concentration with dried blood spots (umol/L) on the second test day with GOLIKE PLUS right before product self-administration and before food intake at 12:00 am (±15 min) on the second test day with Golike Plus
Primary Phe blood concentration with dried blood spots (umol/L) on the second test day with Standard of Care before food intake At 4:00 pm (±15 min) on the second test day with SoC
Primary Phe blood concentration with dried blood spots (umol/L) on the second test day with GOLIKE PLUS before food intake At 4:00 pm (±15 min) on the second test day with Golike Plus
Primary Phe blood concentration with dried blood spots (umol/L) on the second test day with Standard of Care right before product self-administration and before any food intake at 8:00 pm (±15 min) on the second test day with SoC
Primary Phe blood concentration with dried blood spots (umol/L) on the second test day with GOLIKE PLUS right before product self-administration and before any food intake at 8:00 pm (±15 min) on the second test day with Golike Plus
Primary Phe blood concentration with dried blood spots (umol/L) on the day following the second test day with Standard of Care on the following morning, before any food intake. at 8:00 am (±15 min) on the day following the second test day with SoC
Primary Phe blood concentration with dried blood spots (umol/L) on the day following the second test day with GOLIKE PLUS on the following morning, before any food intake. at 8:00 am (±15 min) on the day following the second test day with Golike Plus
Secondary Tyr blood concentration with dried blood spots (umol/L) on the second test day with Standard of Care right before product self-administration and before any food intake at 8:00 am(±15 min) on the second test day with SoC
Secondary Tyr blood concentration with dried blood spots (umol/L)on the second test day with GOLIKE PLUS right before product self-administration and before any food intake at 8:00 am(±15 min)on the second test day with Golike Plus
Secondary Tyr blood concentration with dried blood spots (umol/L)on the second test day with Standard of Care right before product self-administration and before any food intake at 12:00 am(±15 min) on the second test day with SoC
Secondary Tyr blood concentration with dried blood spots (umol/L) on the second test day with GOLIKE PLUS right before product self-administration and before any food intake at 12:00 am(±15 min) on the second test day with Golike Plus
Secondary Tyr blood concentration with dried blood spots (umol/L)on the second test day with Standard of Care before food intake at 4:00 pm(±15 min)on the second test day with SoC
Secondary Tyr blood concentration with dried blood spots (umol/L) on the second test day with GOLIKE PLUS before food intake at 4:00 pm(±15 min)on the second test day with Golike Plus
Secondary Tyr blood concentration with dried blood spots (umol/L)on the second test day with Standard of Care right before product self-administration and before any food intake at 8:00 pm(±15 min) on the second test day with SoC
Secondary Tyr blood concentration with dried blood spots (umol/L)on the second test day with GOLIKE PLUS right before product self-administration and before any food intake at 8:00 pm(±15 min) on the second test day with Golike Plus
Secondary Tyr blood concentration with dried blood spots (umol/L)on the day following the second test day with Standard of Care on the following morning, before any food intake. at 8:00 am(±15 min) on the day following the second test day with SoC
Secondary Tyr blood concentration with dried blood spots (umol/L) on the day following the second test day with GOLIKE PLUS on the following morning, before any food intake. at 8:00 am(±15 min) on the day following the second test day with Golike Plus
See also
  Status Clinical Trial Phase
Recruiting NCT05998109 - PheCheck Feasibility Study
Not yet recruiting NCT04433728 - Life With Phenylketonuria. Adult Neurological Outcome of PCU Screened Patients From 1971 to 2002.
Completed NCT01209819 - Bone Mineral Density in Adults With Hyperphenylalaninemia N/A
Active, not recruiting NCT05174559 - Additional Dietary Large Neutral Amino Acids (LNAA) for Improved Symptoms in Adult Classical Phenylktonuria (PKU) N/A
Not yet recruiting NCT04969809 - Comparison of Atherogenic Risk Factors and Efficacy of Nutritional Treatment Among Adult Phenylketonuria Patients N/A
Recruiting NCT04404530 - Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU)
Active, not recruiting NCT05971563 - Amino Acid Kinetics of GMP-AA in Healthy Human Volunteers N/A
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Completed NCT04368624 - PKU Skin Stripping
Completed NCT04452513 - A Prospective Clinical Study of Phenylketonuria (PKU)
Completed NCT05497050 - The Effect of Nursing Empowerment Program N/A
Completed NCT04943393 - Remote Neurocognitive and Psychological Assessment in PKU
Completed NCT05096988 - Evaluation of PKU Sphere Liquid N/A
Not yet recruiting NCT06332807 - AAV Gene Therapy Clinical Study in Adult Classic PKU Phase 1/Phase 2
Completed NCT00225615 - A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels Phase 3
Recruiting NCT05128149 - Metabolic Control and Patient Well-being in Phenylketonuria: do Guidelines Make a Difference?
Terminated NCT05229549 - Study to Evaluate the Effect on Nitrogen Retention of Two Different Posology Schemes of PKU GOLIKE PLUS 3-16 and Free AAs in Patients With Phenylketonuria N/A
Enrolling by invitation NCT05356377 - Preliminary Study of Brain Effects of Palynziq-Related Changes in Phenylalanine in Individuals With PKU
Not yet recruiting NCT06337864 - Evaluating the Efficacy and Safety of Large Neutral Amino Acids in the Treatment of Classical Phenylketonuria N/A
Completed NCT02445521 - Testing of Four Home Phenylalanine Monitoring Prototype Devices N/A